MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 13, 2008; DOI: 10.1124/mol.108.050625


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.050625v1
74/5/1269    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Rieck, M.
Right arrow Articles by Muller, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rieck, M.
Right arrow Articles by Muller, R.


Received for publication July 16, 2008.
Revised August 11, 2008.
Accepted for publication August 13, 2008.

Ligand-mediated regulation of PPAR{beta}/{delta}: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid (atRA)

Markus Rieck 1, Wolfgang Meissner 1, Simone Ries 1, Sabine Muller-Brusselbach 1, Rolf Muller 2*

1 IMT Marburg 2 Phlipps-Universitat Marburg

* Address correspondence to: E-mail: rmueller{at}imt.uni-marburg.de

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily that modulate target gene expression in response to natural fatty acid ligands and synthetic agonists. Intriguingly, all trans-retinoic acid (atRA) has recently been reported to act as a ligand for PPAR{beta}/{delta}, to activate its transcriptional activity and, in contrast to the "classical" function of atRA, to stimulate cell proliferation (Schug et al., 2007). Here, we report that in contrast to synthetic PPAR{beta}/{delta} agonists, atRA failed to induce the transcriptional activity of {beta}/{delta} using different types of reporter gene assays. Similarly, atRA did not affect the expression of the bona fide PPAR{beta}/{delta} target genes ADRP and ANGPTL4, but strongly increased expression of the retinoic acid target gene CYP26A under the identical experimental conditions. Consistent with these observations, atRA did not compete with established PPAR{beta}/{delta} agonists in a ligand binding assay, and atRA did not enable the interaction of PPAR{beta}/{delta} with a co-activator peptide in a time resolved fluorescence resonance energy transfer assay in vitro. These results are in sharp contrast to the effect of established PPAR{beta}/{delta} agonists in both in vitro assays. Collectively, these data strongly suggest that atRA does not function as a ligand of PPAR{beta}/{delta} in any of the experimental systems tested, and that the previously reported atRA effects are more likely to reflect an uncharacterized and less direct mechanism.


Key words: PPARs, Transcriptional coactivators, DNA binding sites, Promoter analysis


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. G. Borland, J. E. Foreman, E. E. Girroir, R. Zolfaghari, A. K. Sharma, S. Amin, F. J. Gonzalez, A. C. Ross, and J. M. Peters
Ligand Activation of Peroxisome Proliferator-Activated Receptor-{beta}/{delta} Inhibits Cell Proliferation in Human HaCaT Keratinocytes
Mol. Pharmacol., November 1, 2008; 74(5): 1429 - 1442.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics